You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis

Article metrics

Article menu

Download PDFPDF

Oral Presentations
Still breaking news on TNF inhibitors in rheumatoid arthritis
OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 20176507
Jul 20174603
Aug 20172603
Sep 20175607
Oct 20175202
Nov 20174204
Dec 20171800
Jan 20183000
Feb 20183402
Mar 20182401
Apr 20184802
May 20183602
Jun 20185802
Jul 20186205
Aug 20188802
Sep 201894030
Oct 2018110022
Nov 201856013
Dec 201860013
Jan 201968016
Feb 2019151037
Mar 201973024
Apr 201968021
May 20195005
Jun 201977010
Jul 201980018
Aug 201942014
Sep 20193209
Oct 201973013
Nov 20195408
Dec 20196105
Jan 202053012
Feb 20201808
Mar 2020202
Apr 202032014
May 202030017
Jun 20204805
Jul 20203407
Aug 20203006
Sep 20203000
Oct 20204207
Nov 20201002
Dec 20203403
Jan 20212206
Feb 20211404
Mar 20212007
Apr 20213203
May 20211704
Jun 2021206
Jul 2021105
Aug 2021204
Sep 2021206
Oct 202119022
Nov 202116017
Dec 20211303
Jan 2022201
Feb 20221000
Mar 20221305
Apr 20222001
May 202230013
Jun 20222004
Jul 20222101
Aug 20223803
Sep 202224012
Oct 202221012
Nov 20221609
Dec 20221802
Jan 20231201
Feb 2023600
Mar 20231501
Apr 2023601
May 20231104
Jun 2023804
Jul 2023405
Aug 2023702
Sep 2023600
Oct 2023402
Nov 20232204
Dec 20231203
Jan 20242301
Feb 2024701
Mar 20244007
Total27730569